Press coverage about AxoGen (NASDAQ:AXGN) has trended somewhat positive this week, Accern Sentiment reports. The research group ranks the sentiment of media coverage by monitoring more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. AxoGen earned a news impact score of 0.14 on Accern’s scale. Accern also assigned news stories about the medical equipment provider an impact score of 48.0631244690965 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the immediate future.

These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:

AxoGen (AXGN) traded up 0.33% on Friday, reaching $15.10. The company’s stock had a trading volume of 139,976 shares. The firm’s 50-day moving average price is $15.85 and its 200 day moving average price is $12.90. The company’s market cap is $501.92 million. AxoGen has a 52-week low of $7.65 and a 52-week high of $17.25.

AxoGen (NASDAQ:AXGN) last issued its quarterly earnings data on Wednesday, August 2nd. The medical equipment provider reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.08) by $0.02. The firm had revenue of $15.20 million during the quarter, compared to analyst estimates of $14.40 million. AxoGen had a negative return on equity of 114.64% and a negative net margin of 27.50%. The company’s revenue for the quarter was up 46.2% on a year-over-year basis. During the same period in the previous year, the company posted ($0.09) EPS. Equities analysts anticipate that AxoGen will post ($0.31) EPS for the current fiscal year.

A number of research firms recently issued reports on AXGN. BidaskClub downgraded AxoGen from a “strong-buy” rating to a “buy” rating in a report on Friday, July 28th. Cantor Fitzgerald initiated coverage on AxoGen in a report on Thursday, June 29th. They set an “overweight” rating and a $18.00 price objective for the company. Leerink Swann initiated coverage on AxoGen in a research note on Monday, July 31st. They issued an “outperform” rating and a $22.00 price target for the company. ValuEngine upgraded AxoGen from a “sell” rating to a “hold” rating in a research note on Friday, June 2nd. Finally, Wedbush restated an “outperform” rating and issued a $14.00 price target (down from $17.00) on shares of AxoGen in a research note on Friday, May 19th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. AxoGen currently has a consensus rating of “Buy” and a consensus target price of $15.90.

TRADEMARK VIOLATION NOTICE: This piece of content was published by Daily Political and is the property of of Daily Political. If you are reading this piece of content on another publication, it was illegally stolen and republished in violation of United States and international copyright law. The correct version of this piece of content can be read at

Insider Buying and Selling by Quarter for AxoGen (NASDAQ:AXGN)

Receive News & Ratings for AxoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AxoGen Inc. and related companies with's FREE daily email newsletter.